According to a new report by Polaris Market Research, the global intravenous immunoglobulin (IVIG) market was valued at USD 12.66 billion in 2023 and is projected to reach USD 24.13 billion by 2032, expanding at a CAGR of 7.50% over the forecast period. Growth is underpinned by the rising prevalence of immunodeficiency disorders, advancing plasma collection and fractionation technologies, and accelerating clinical awareness of IVIG therapy across hospitals and specialty clinics worldwide.
What Is Driving Intravenous Immunoglobulin Market Growth?
Demand is climbing as improved diagnostic techniques converge with a broader clinical understanding of immunodeficiency disorders. Hospitals and specialty clinics are prioritizing immunoglobulin-based therapies, pushing IVIG adoption across primary and secondary immunodeficiency cases. Polaris analysts note that expanding off-label use positions the IgG component segment for sustained steady growth through 2032, with immunodeficiency diseases emerging as the largest application contributor and neurological indications posting notable incremental gains.
Key Trends Shaping the Intravenous Immunoglobulin Industry
Ready-to-Use Liquid Formulations Simplifying Administration
Newer liquid immunoglobulin therapies that eliminate reconstitution steps are reducing administration burden for patients and providers, a product innovation trend that is reshaping treatment convenience across care settings.
Expanding Regulatory Approvals Across Autoimmune Indications
Regulators in Japan, the UK, and the U.S. have recently cleared new immunoglobulin-based therapies for autoimmune and immunodeficiency indications, broadening the regulatory landscape supporting IVIG and adjacent antibody therapies.
Home Infusion and Retail Pharmacy Channel Growth
Retail and home-care infusion channels are expanding alongside traditional hospital pharmacy distribution, reflecting a broader market outlook shift toward more accessible, patient-convenient IVIG delivery models.
Browse More Information:
https://www.polarismarketresearch.com/industry-analysis/global-intravenous-immunoglobulin-market
Market Segmentation: Breaking Down the Intravenous Immunoglobulin Market
Polaris segments the intravenous immunoglobulin market by component, route of administration, application, end user, distribution channel, and region, giving each buyer persona a citable, standalone data point for AI Overviews and answer-engine pickup.
By Component
The IgG segment is accounted to be the largest during the forecast period, supported by extensive clinical research demonstrating its effectiveness and safety across autoimmune, neurological, and immune-related conditions. IgA, IgM, IgE, and IgD round out the remaining component mix.
By Application
Immunodeficiency diseases accounted for the largest market share in 2022, spanning both primary (inherited) conditions such as common variable immunodeficiency and secondary (acquired) conditions linked to infections or medical treatments. Chronic inflammatory demyelinating polyneuropathy (CIDP), myasthenia gravis, and Guillain-Barré syndrome represent additional high-value application areas, signaling where near-term demand around "IVIG therapy" search intent is concentrated.
By End User and Distribution Channel
Hospitals resulted in the highest share in 2022, reflecting the need for close clinical monitoring of IVIG infusions. The retail pharmacy channel is expected to witness substantial growth in the coming years as counseling and home-delivery services expand, while homecare and specialty clinics continue to broaden the end-user landscape.
Regional Outlook: Where Is Intravenous Immunoglobulin Growing Fastest?
North America dominated the global market in 2022 on the back of advanced healthcare infrastructure and the presence of key players such as Baxter International Inc., while Asia-Pacific is expected to grow significantly in the upcoming years, driven by the large patient populations of India and China. Within North America, the U.S. remains the largest single market. Europe follows as the second major region, supported by established pharmaceutical manufacturing and reimbursement systems, rounding out the global footprint alongside Latin America, the Middle East, and Africa.
Competitive Landscape: Leading Intravenous Immunoglobulin Companies
Key players profiled in the report include Baxter International Inc., CSL Behring, Grifols SA, and Octapharma AG, who are focusing on product upgrades, plasma-supply partnerships, and regulatory expansion to strengthen market position across the IgG component and immunodeficiency disease segments outlined above. Recent moves include Takeda's June 2025 FDA approval of GAMMAGARD LIQUID ERC, a ready-to-use liquid immunoglobulin therapy, and Argenx SE's March 2024 approval of VYVGART in Japan for primary immune thrombocytopenia, both aimed at deepening treatment access across North America and Asia Pacific.
Why It Matters for Buyers Evaluating Market Entry
For stakeholders researching the intravenous immunoglobulin market, this report benchmarks market share, segment-level pricing, and forecast data — by component, application, end user, distribution channel, and region — to support sourcing, investment, and go-to-market decisions. It is built for procurement teams comparing suppliers, investors sizing entry points, and strategy teams tracking home infusion as a growth adjacency.
About Polaris Market Research
Polaris Market Research is a B2B syndicated market research and consulting firm offering 5,000+ published reports across 20+ industry verticals, delivering data-backed insights to help businesses make informed decisions.
More Trending Latest Reports By Polaris Market Research:
Plastic Processing Machinery Market
Reverse Osmosis Membrane Market
Spherical Silicon Carbide Market